Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 30 points (0.2%) at 16,949 as of Wednesday, Aug. 20, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,346 issues advancing vs. 1,589 declining with 185 unchanged. The Health Services industry currently sits down 0.4% versus the S&P 500, which is up 0.1%. A company within the industry that increased today was Express Scripts ( ESRX), up 0.6%. On the negative front, top decliners within the industry include Intuitive Surgical ( ISRG), down 1.1%, Waters ( WAT), down 1.0%, Agilent Technologies ( A), down 0.8%, Abbott Laboratories ( ABT), down 0.8% and WellPoint ( WLP), down 0.7%. TheStreet would like to highlight 3 stocks pushing the industry higher today: 3. Grifols ( GRFS) is one of the companies pushing the Health Services industry higher today. As of noon trading, Grifols is up $0.30 (0.8%) to $37.55 on light volume. Thus far, 265,951 shares of Grifols exchanged hands as compared to its average daily volume of 722,100 shares. The stock has ranged in price between $37.10-$37.72 after having opened the day at $37.30 as compared to the previous trading day's close of $37.25. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the United States, Canada, and internationally. Grifols has a market cap of $12.4 billion and is part of the health care sector. Shares are down 0.1% year-to-date as of the close of trading on Tuesday. Currently there are 4 analysts who rate Grifols a buy, no analysts rate it a sell, and none rate it a hold. TheStreet Ratings rates Grifols as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, reasonable valuation levels, increase in stock price during the past year and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Grifols Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.